title,"Sponsors / Collaborators","Phase of Development","Clinical Trial Link","Mechanism of Action","Populations Tested In","FDA Designation","Nonprofit/Government Support","Presented at meetings",Location,"Mechanism Description","Phase of Development Devices","Type of Drug/Device",field_type_of_device_technique,US,"ct description",Software/Hardware/Both,"ex-US Approval","Year on Market" "Cenobamate - YKP3089 - XCOPRI","SK Life Sciences, Inc","Phase 3",https://ClinicalTrials.gov/show/NCT02535091,"Ion Channel","Drug-resistant focal seizures",,N/A,"AEDD 2019","Over 119 Clinical Sites, click on clinical trials link to learn more.",": Blocks sodium channels form being inactivated","On Market","New Molecular Entity",,yes,,N/A,,